Rexulti Half-Life
The elimination half-life of Rexulti (brexpiprazole) is 91 hours (approximately 3.8 days), with its major metabolite DM-3411 having a half-life of 86 hours 1.
Key Pharmacokinetic Details
Time to Steady State:
- Brexpiprazole reaches steady-state concentrations within 10 to 12 days of once-daily dosing 1
- This prolonged time to steady state is a direct consequence of the long elimination half-life
Peak Concentrations:
- Peak plasma concentrations (Tmax) occur within 4 hours after oral administration 1
- The median tmax in Japanese patients was 4-5 hours across all doses 2
Clinical Implications of the Long Half-Life
Dosing Considerations:
- The 91-hour half-life means the drug accumulates 2.5- to 5.5-fold by day 14 compared to day 1 2
- Steady-state levels are not achieved until after 10 days, so clinical effects may be delayed
- Any dose adjustments should be made no more frequently than every 10-12 days to allow for equilibration
Drug Interactions:
- Brexpiprazole is metabolized primarily by CYP3A4 and CYP2D6 1
- Strong inhibitors of both enzymes can increase exposure up to 5.1-fold in extensive CYP2D6 metabolizers 1
- The long half-life amplifies the clinical significance of drug interactions, as accumulation occurs over weeks
Discontinuation:
- Due to the 91-hour half-life, brexpiprazole will remain in the system for approximately 2-3 weeks after the last dose (approximately 5 half-lives for complete elimination)
- This extended washout period is relevant when switching to other antipsychotics or managing adverse effects
Metabolite Information
The major metabolite DM-3411 has a similar half-life of 86 hours and represents 23-48% of brexpiprazole exposure at steady state, though it does not contribute to therapeutic effects 1.